Use of circulating tumor cells in prospective clinical trials for NSCLC patients - standardization of the pre-analytical conditions.

Véronique HofmanVéronique HofmanSylvie LeroyCharlotte CohenSimon HeekeFlorian CattetCoraline BenceSalomé LalvéeJérôme MourouxCharles-Hugo MarquettePaul Hofmannull null

Published in: Clinical chemistry and laboratory medicine (2019)

The BCT tubes gave a high yield and preserved the integrity of CTCs after 24 and 48 h of storage at room temperature, which facilitate their molecular characterization in NSCLC patients entering clinical trials.

Keyphrases

circulating tumor cells
clinical trial
end stage renal disease
room temperature
small cell lung cancer
newly diagnosed
chronic kidney disease
ejection fraction
prognostic factors
randomized controlled trial
patient reported outcomes
ionic liquid
patient reported
cell free
phase iii
brain metastases